ARCT News and Press, Arcturus Therapeutics Ltd. From 11/02/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips A strategic collaboration has today’s traders talking about Arcturus Therapeutics (NASDAQ: ARCT ) and CSL (OTCMKTS: CSLLY ). Reportedly, the two companies will work together on mRNA technology for a w...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com It’s time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday! Moving stocks this morning are acquisitions, collaborations, a...

Arcturus Therapeutics ( NASDAQ: ARCT ) surges 32,4% after-hours on Tuesday after the firm enters a strategic collaboration with CSL Seqirus to provide former with a license to their self-amplifying mRNA technology to support the research, development, manufacture, and...

Arcturus to receive upfront payment of $200 million and more than $4 billion in potential development and commercial milestones 40% profit sharing for COVID-19 vaccines, up to double digit royalties for influenza, pandemic preparedness and three additional respiratory infect...

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology PR Newswire KING OF PRUSSIA, Pa. , Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory r...

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disea...

Arcturus Therapeutics ( NASDAQ: ARCT ) said on Wednesday it had obtained an award for up to $63.2M from the Biomedical Advanced Research and Development Authority. ( ARCT ) rose ~6% after the bell. The award will be provided over three years to support prec...

Arcturus will expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform with the support of the Biomedical Advanced Research and Development Authority $63.2 Million base award to f...